Cargando…

Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer

Androgen receptor (AR) splice variants (ARVs) are implicated in development of castration-resistant prostate cancer (CRPC). Upregulation of ARVs often correlates with persistent AR activity after androgen deprivation therapy (ADT). However, the genomic and epigenomic characteristics of ARV-dependent...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Yundong, Lu, Ji, Ye, Zhenqing, Hao, Siyuan, Wang, Liewei, Kohli, Manish, Tindall, Donald J, Li, Benyi, Zhu, Runzhi, Wang, Liguo, Huang, Haojie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Molecular Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5829742/ https://www.ncbi.nlm.nih.gov/pubmed/29309643 http://dx.doi.org/10.1093/nar/gkx1306

Ejemplares similares

Plasma cell-free DNA–based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer
por: Du, Meijun, et al.
Publicado: (2020)

TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration‐Resistant Prostate Cancer
por: Qin, Sisi, et al.
Publicado: (2017)

Posttranslational Modification of the Androgen Receptor in Prostate Cancer
por: van der Steen, Travis, et al.
Publicado: (2013)

Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer
por: Zhao, Jingwen, et al.
Publicado: (2016)

Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer
por: Zhao, Yu, et al.
Publicado: (2014)

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein
por: Zhang, Ying, et al.
Publicado: (2022)

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Abiraterone Rechallenge Based on Sequential Testing of Androgen Receptor Splice Variant 7 Expression in Circulating Tumor Cells: A Case Report
por: Nagaya, Naoya, et al.
Publicado: (2020)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: He, Yundong, et al.
Publicado: (2021)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment
por: Sicotte, Hugues, et al.
Publicado: (2022)

Abiraterone acetate, an inhibitor of adrenal androgen synthesis in “hormone refractory prostate cancer”
por: Goel, Arun Kumar, et al.
Publicado: (2011)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Redirecting abiraterone metabolism to fine tune prostate cancer anti-androgen therapy
por: Li, Zhenfei, et al.
Publicado: (2016)

Genotoxic stress causes the accumulation of the splicing regulator Sam68 in nuclear foci of transcriptionally active chromatin
por: Busà, Roberta, et al.
Publicado: (2010)

Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor
por: Hu, Zengchun, et al.
Publicado: (2021)

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Binder, Moritz, et al.
Publicado: (2016)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
por: Rehman, Yasser, et al.
Publicado: (2012)

Splicing factor PRPF6 upregulates oncogenic androgen receptor signaling pathway in hepatocellular carcinoma
por: Song, Huijuan, et al.
Publicado: (2020)

Prognostic association of plasma cell free DNA based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration resistant prostate cancer patients
por: Kohli, Manish, et al.
Publicado: (2018)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Abiraterone Acetate
Publicado: (2012)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Androgen receptor signaling in prostate cancer development and progression
por: Lonergan, Peter E, et al.
Publicado: (2011)

Biomarker-Based Targeting of the Androgen-Androgen Receptor Axis in Advanced Prostate Cancer
por: Kohli, Manish, et al.
Publicado: (2012)

Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer
por: Liu, Chengfei, et al.
Publicado: (2016)

A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells
por: Li, Tzu-Huey, et al.
Publicado: (2007)

Constitutively Active Androgen Receptor in Hepatocellular Carcinoma
por: Montgomery, Emma J., et al.
Publicado: (2022)

Low cost abiraterone
por: Barreiro, Diego Martin, et al.
Publicado: (2015)

Abiraterone-Induced Endocrinopathies
por: Decamps, Scarlett, et al.
Publicado: (2023)

Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
por: Pezaro, C, et al.
Publicado: (2013)

Chromatin: the old and young of it
por: Emerson, Felicity J., et al.
Publicado: (2023)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023)

Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
por: Huang, Jian, et al.
Publicado: (2022)

Constitutive androstane receptor 1 is constitutively bound to chromatin and ‘primed’ for transactivation in hepatocytes
por: McMahon, Michael, et al.
Publicado: (2019)

Measure transcript integrity using RNA-seq data
por: Wang, Liguo, et al.
Publicado: (2016)

Comparison of cell response to chromatin and DNA damage
por: Luzhin, Artyom, et al.
Publicado: (2023)

Profiling and characterization of constitutive chromatin-enriched RNAs
por: Shen, Wenlong, et al.
Publicado: (2022)

Intracrine androgen biosynthesis in renal cell carcinoma
por: Lee, Geun Taek, et al.
Publicado: (2017)

Androgen-Receptor Positive Lacrimal Sac Adenocarcinoma Demonstrating Long-Lasting Response to LHRH Analog Plus Abiraterone Treatment
por: Vagia, Elena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jqlkm82dvi6k2vffgas2jdc5eq